BEDMINSTER, NJ-Archimedes Pharma, an international specialtypharmaceutical company, has leased 14,000 square feet at OneCrossroads Dr. here. The long-term commitment marks the company’sforay into the US and follows an extensive site search in NewJersey and Pennsylvania; a BEIP grant from the New Jersey EconomicDevelopment Authority was the material factor in ArchimedesPharma’s ultimate selection of the Garden State for its newoffice.

|

Cushman & Wakefield’s Ron Ganter, Tom Giannone and ChrisKinum--all members of the firm’s Global Life Science Practice groupbased in East Rutherford, NJ--represented Archimedes Pharma in thetransaction. Cushman & Wakefield’s Bill Brown and Josh Cohen,based in Morristown, NJ, served as representatives for propertyowner Spear Street Capital.

|

“After an aggressive, six-month search for the right location,Archimedes Pharma found its US home at One Crossroads,” Gantersays, adding that this class A property is situated within NewJersey’s pharmaceutical life science corridor.

|

The NJ EDA awarded Archimedes a Business Employment IncentiveProgram grant for its commitment to add up to 75 new jobs inBedminster. “We were able to work efficiently to secure theincentives, which ultimately enticed our client to choose NewJersey,” Ganter tells GlobeSt.com.

|

The Cushman & Wakefield team worked closely with ArchimedesPharma’s Jeff Buchalter, president and CEO, and Steve Kanovsky,in-house general counsel, during the assignment.

|

Want to continue reading?
Become a Free ALM Digital Reader.

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.